# Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

> **NCT01345019** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 1718 (actual)

## Conditions studied

- Cancer
- Hematologic Malignancies
- Multiple Myeloma
- Oncology
- Bone Metastases
- Multiple Myeloma Bone Lesions

## Interventions

- **DRUG:** Denosumab
- **DRUG:** Zoledronic acid
- **DRUG:** Placebo to Denosumab
- **DRUG:** Placebo to zoledronic acid
- **DRUG:** Denosumab (for the open-label treatment phase)

## Key facts

- **NCT ID:** NCT01345019
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-17
- **Primary completion:** 2016-07-19
- **Final completion:** 2019-03-29
- **Target enrollment:** 1718 (ACTUAL)
- **Last updated:** 2022-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01345019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01345019, "Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01345019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*